Art

J-GLOBAL ID：201802219206786018   Reference number：18A1416955

Perioperative safety and hemostatic efficacy of Advate in patients with hemophilia A in a postmarketing surveillance in Japan

日本の市販後調査での血友病A患者におけるアドベイトの周術期の安全性と止血効能

Author (13)： NOGAMI Keiji (Nara Medical Univ., Kashihara, JPN) ,  TAKEDANI Hideyuki (Univ. Tokyo, Tokyo, JPN) ,  SHIMA Midori (Nara Medical Univ., Kashihara, JPN) ,  YOSHIOKA Akira (Nara Medical Univ., Kashihara, JPN) ,  MATSUSHITA Tadashi (Nagoya Univ. Hospital, Nagoya, JPN) ,  TAKAMATSU Junki (Japanese Red Cross Tokai-Hokuriku Block Blood Center, Seto, JPN) ,  TAKI Masashi (St. Marianna Univ. School of Medicine Yokohama City Seibu Hospital, Yokohama, JPN) ,  FUKUTAKE Katsuyuki (Tokyo Medical Univ. Hospital, Tokyo, JPN) ,  UCHIKAWA Haruhiko (Shire Japan K.K., Tokyo, JPN) ,  TAKAGI Hiroshi (Shire Japan K.K., Tokyo, JPN) ,  ARAI Morio (Shire Japan K.K., Tokyo, JPN) ,  ENGL Werner (Baxalta Innovations GmbH, Vienna, AUT) ,  SHIRAHATA Akira (Kitakyushu Yahata Higashi Hospital, Kitakyushu, JPN)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 108  Issue： 1  Page： 22-29  Publication year： Jul. 2018 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： hereditary disease ,...
Semi thesaurus term： *Hemophilia A ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1416955&from=J-GLOBAL&jstjournalNo=F0888A") }}

JST classification (2)： Drug therapy(=pharmacotherapy)for hematologic diseases in general  (GK05020P) ,  Clinical application of drugs acting on blood and body fluid  (GW14020X)

Reference (22)：

• Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10:428-37.
• Blanchette VS, Shapiro AD, Liesner RJ, et al. on behalf of the rAHF-PEM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated paediatric patients. J Thromb Haemost 2008; 6:1319-26.
• Dhillon S. Octocog Alfa, Antihaemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE®) A Review of its use in the management of patients with haemophilia A. Drugs. 2012;72:987-1007.
• Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol. 2007;136:777-87.
• Tabibian S, Motlagh H, Naderi M, Dorgalaleh A. Intracranial hemorrhage in congenital bleeding disorders. Blood Coagul Fibrinolysis. 2017. https://doi.org/10.1097/MBC.0000000000000660.

Terms in the title (9)： 日本 ,  市販後調査 ,  血友病A ,  患者 ,  ベイト ,  周術期 ,  安全性 ,  止血 ,  効能